![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » SYNOVICS RECEIVES APPROVAL FOR GENERIC METFORMIN
SYNOVICS RECEIVES APPROVAL FOR GENERIC METFORMIN
August 1, 2006
Synovics Pharmaceuticals announced that the FDA has approved its generic version of metformin extended-release tablets in 500 mg. Bristol-Myers Squibb markets the equivalent listed drug, Glucophage XR.
Metformin is a member of the biguanide drug class, which represents the current standard for Type 2 diabetes management. The U.S. market for extended-release metformin is estimated to exceed $150 million annually.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct